Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis

Last updated: February 24, 2025
Sponsor: Wake Forest University Health Sciences
Overall Status: Active - Recruiting

Phase

1

Condition

Interstitial Cystitis

Gynecological Infections

Bladder Disorders

Treatment

Placebo Capsules

Desert Harvest Aloe Vera Capsules

Clinical Study ID

NCT04734106
IRB00069987
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to assess the safety and efficacy of super-concentrated, freeze-dried aloe vera capsules for treatment of interstitial cystitis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Females or males, aged 18 years or older

  • Females of childbearing potential must agree to use acceptable methods of birthcontrol. Acceptable methods are oral and injectable preparations, double barrier,vasectomized partner, or abstinence.

  • Participant must sign and date the informed consent.

  • Participant must report a urinary frequency of at least 11 times per 24-hour day, onaverage over the previous four weeks.

  • Participant must report a pain/discomfort score of 4 or greater on a 0-9 Likertscale.

  • These reported urinary symptoms of frequency and pain/discomfort must have beenpresent for at least the previous 24 weeks prior to the first baseline screeningvisit.

  • Participants must report in the baseline voiding diary at least one voided volumegreater than or equal to 75cc in a 24-hour period.

Exclusion

Exclusion Criteria:

  • Known allergy or intolerance to aloe vera in any form as reported by the participantor derived from medical records.

  • History of Bladder tumors (malignant or benign).

  • Current active bladder or urethral calculus.

  • History of urethral cancer within the previous five years.

  • Any disease which, in the opinion of the investigator, may be unstable or havebearing on the outcome of the study, including severe debilitating concurrentmedical conditions such as coronary artery disease, azotemia, moderate to severehepatic insufficiency, etc.

  • Previous treatment with Cytoxan (cyclophosphamide).

  • History of cyclophosphamide or chemical cystitis or tuberculosis or radiationcystitis.

  • History of pelvic radiation treatment, bladder cancer or cancer in situ, or urethralcancer.

  • History of any other neoplastic process currently requiring systemic,nonprophylactic treatment.

  • History of urethral diverticulum.

  • Inability to void spontaneously.

  • Subjects with interstitial cystitis symptoms alleviated by current therapy regimen.

  • Uncontrolled diabetes mellitus.

  • Previous enrollment in an aloe vera study.

  • Previous use of Desert Harvest super-concentrated, freeze-dried aloe vera capsules.

  • Any imminent change in residence that could compromise compliance.

  • Unlikely to be compliant due to unmanaged medical or psychological problem,including dementia, aphasia, or other deficits of cognition or speech/languagefunction that will interfere with the participant's ability to complete the study.

  • Substance abuse or dependency problem within the past two years for which patientreceived no treatment.

Male-Specific Exclusion Criteria:

  • Males with a history of prostate cancer within the previous five years.

  • Males with a prostatic infection within the previous three months.

Female-Specific Exclusion Criteria:

  • Females with a history of uterine, cervical, or vaginal cancer within the previousfive years.

  • Pregnant or lactating females.

Study Design

Total Participants: 100
Treatment Group(s): 2
Primary Treatment: Placebo Capsules
Phase: 1
Study Start date:
February 18, 2025
Estimated Completion Date:
July 31, 2027

Study Description

After being informed about the study and potential risks, all participants who have provided written informed consent will be screened to determine eligibility for study entry. Participants who meet the eligibility requirements will be randomized in a double-blind manner (participant and investigator) in a 4:1 ratio to aloe vera (study group) or placebo (control group), respectively. The dosing regimen will be increased by 3 capsules every month for 3 months and then reduced by 2 capsules every week during the fourth month for both groups. Participants will remain in the study for sixteen weeks.

Connect with a study center

  • Wake Forest Baptist Hospital

    Winston-Salem, North Carolina 27157
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.